{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040956","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.515180+00:00","generated_at":"2026-06-11T18:58:29.396532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025","bullets":["Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.","Cash and marketable securities $207.6M at June 30, expected to fund operations into 2025.","CFO Ajim Tamboli resigned; no replacement announced yet.","Initial Phase 1/2 data for MRT-2359 expected H2 2023; IND for MRT-6160 expected H1 2024.","FDA Orphan Drug Designation for MRT-2359 for small cell lung cancer received."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040956","json":"https://secwatch.observer/filing/0000950170-23-040956.json","markdown":"https://secwatch.observer/filing/0000950170-23-040956.md","text":"https://secwatch.observer/filing/0000950170-23-040956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/0000950170-23-040956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/glue-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:58:29.396532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ab3047336b82c5a65ed996c947bd8b6a543183e","claim":"Monte Rosa Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $35.2 million.","evidence_excerpt":"Net loss for the second quarter of 2023 was $35.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/0000950170-23-040956-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$35.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}